Trial Profile
A multinational double blind placebo-controlled, parallel group study to evaluate the efficacy and safety of CCX282B in subjects with moderate to severe Crohn's disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Vercirnon (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms PROTECT-1
- Sponsors ChemoCentryx
- 20 Oct 2014 Results published in a ChemoCentryx media release.
- 29 Jun 2012 Planned number of patients changed from 423 to 598 as reported by ClinicalTrials.gov.
- 27 Oct 2010 One-year results have been presented at the United European Gastroenterology Federation meeting according to a ChemoCentryx media release. The results are discussed further within the media release.